Ranch Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Ranch Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$5K	–	578
2021 Q3	$5K	Hold	300	–	–	﹤0.01%	552
2021 Q2	$6K	Sell	300 -75	-20%	-$1.34K	﹤0.01%	732
2021 Q1	$5K	Buy	+375	New	+$6.07K	﹤0.01%	746

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ranch Capital Advisors's VNDA Position: Q4 2021 in Review

Ranch Capital Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 300 shares — an estimated $5K sold.

Ranch Capital Advisors first reported a position in VNDA in Q1 2021 and held it in 3 quarters. The position peaked at $6K in Q2 2021. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

Ranch Capital Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ranch Capital Advisors sold 300 Vanda Pharmaceuticals shares in Q4 2021, an estimated $5K.
Ranch Capital Advisors first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Ranch Capital Advisors's Vanda Pharmaceuticals position peaked at $6K in Q2 2021.
198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Ranch Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.